DIRS.INFO The most relevant business & tech news

☆ Novartis lifts sales growth target to 5% per year through 2027
▼ + stars: | 2023-11-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +1 min

The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau/File Photo Acquire Licensing RightsCompanies Novartis AG FollowSandoz GmbH FollowFRANKFURT, Nov 28 (Reuters) - Novartis (NOVN.S) has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after it sold off its generic-drugs business. The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs, led by Kisqali, it said in a presentation on Tuesday. The sales forecast, up from a previous revenue growth target of 4% through 2027, is also underpinned by demand for Pluvicto, a precision radiotherapy against prostate cancer, and self-administered multiple sclerosis (MS) shot Kesimpta. Reporting by Ludwig Burger; Editing by Miranda Murray and Miral FahmyOur Standards: The Thomson Reuters Trust Principles.

Persons: Charles Platiau, Kisqali, Vas, Kesimpta, drugmaker, Sandoz, Ludwig Burger, Miranda Murray, Miral Organizations: Swiss, Novartis, REUTERS, Companies Novartis, Sandoz, FRANKFURT, Thomson Locations: Rueil, Malmaison, Paris, France, Basel, Swiss

☆ Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease
▼ + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added. Additional reporting by Miranda Murray; Editing by Kim Coghill, Sonali Paul and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.

Persons: Novartis, Vas Narasimhan, Narasimham, atrasentan, Narasimhan, Kisqali, Roche, Vera, Muddy Waters, Miranda Murray, Kim Coghill, Sonali Paul, Alexander Smith Organizations: Novartis, Chinook Therapeutics, Vera Therapeutics, Sandoz, Chinook, Thomson Locations: Seattle, United States

☆ Novartis to buy Chinook for up to $3.5 bln in boost to late-stage pipeline
▼ + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

June 12 (Reuters) - Novartis (NOVN.S) has agreed to acquire Seattle-based biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease. Chinook is also working on zigakibart, another experimental IgAN treatment that is injected, and plans to start a Phase 3 trial in the third quarter of 2023. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to dialysis or kidney transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, the company added. Additional reporting by Miranda Murray; Editing by Kim Coghill and Sonali PaulOur Standards: The Thomson Reuters Trust Principles.

Persons: Swiss drugmaker, Vas Narasimhan, atrasentan, Narasimhan, Kisqali, Soliris, Miranda Murray, Kim Coghill, Sonali Paul Organizations: Novartis, Seattle, Chinook Therapeutics, Chinook, Swiss pharma, Sandoz, Thomson Locations: Swiss, IgAN, United States

☆ Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
▼ + stars: | 2023-06-02 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. Kisqali has been approved to treat hormone-driven breast cancer that has spread to other parts of the body, where Novartis has taken market share from Pfizer's (PFE.N) Ibrance. But that is in a subset of women who are at high risk of recurrence after surgery, typically diagnosed based on signs of cancer in the lymph nodes. Here, Novartis will face tough competition because the U.S. drugmaker has said Verzenio reduces the risk of recurrence by 35% in that group. Novartis will request approval for wider use in the U.S. and Europe before the end of the year, it added.

Persons: Kisqali, Eli Lilly, Verzenio, drugmaker, Eli Lilly's Verzenio, Jeff Legos, Vas, Ludwig Burger, Sriraj Organizations: Novartis, American Society of Clinical Oncology, Oncology, Hematology, Thomson Locations: FRANKFURT, Chicago, U.S, Europe

☆ Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows
▼ + stars: | 2023-06-02 | by ( Jen Christensen | ) edition.cnn.com time to read: +6 min

CNN —A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the cancer returning after treatment, according to a new study. HR+/HER2- breast cancer has tested positive for progesterone and estrogen receptors and negative for HER2. Endocrine therapy generally works well, but for patients with HR+ or HER- breast cancer, there’s still a 10% to 40% chance that the cancer will come back, some studies show. The new trial found that when Kisqali is added to endocrine therapy, it reduces the risk of recurrence by 25% across a broad population of patients with early breast cancer. About 90% of patients who have breast cancer are diagnosed in the early stages.

Persons: there’s, Kisqali, ”, Dennis J, Slamon, Sara Tolaney, ” Tolaney, Anupama Goel, Goel, Dr, Sanjay Gupta, Alberto Montero, ” Montero, Montero Organizations: CNN, US Food and Drug Administration, American Society of Clinical Oncology, Novartis, UCLA, Comprehensive Cancer Center, Oncology, Dana, Farber Cancer Institute, Mount Sinai Tisch Cancer Center, CNN Health, UH Seidman Cancer Center, Case Western Reserve University School of Medicine Locations: Chicago, Ohio, –

☆ Novartis CEO Vas Narasimhan on the latest research on a breast cancer drug
▼ + stars: | 2023-06-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO Vas Narasimhan on the latest research on a breast cancer drugNovartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the latest research that finds Kisqali - a breast cancer drug made by the company - lowers the risk of recurrence by 25%.

Persons: Vas, Vas Narasimhan Organizations: Novartis

☆ ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
▼ + stars: | 2023-05-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world's biggest cancer research conference in Chicago, starting Thursday. The pair has already has won regulatory approval for Enhertu for metastatic HER2-low breast cancer, but the companies are also studying its use in a variety other HER2 tumors in breast cancers. Lilly's drug, Verzenio, is used in high-risk patients with HR-positive HER2-negative breast cancer that is more likely to reoccur and has already breached the patient's lymph nodes. In a research note earlier this month, Guggenheim analyst Seamus Fernandez said Kisqali is already taking market share from Pfizer's Ibrance in metastatic breast cancer. Merck's Keytruda is also being watched for what benefits it could offer early-stage lung cancer patients .

☆ Novartis buoyed by trial success in early-stage breast cancer
▼ + stars: | 2023-03-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

The Swiss firm's shares jumped 5.8% on Monday to a four-week high by 0734 GMT, after it said a panel of independent supervisors recommended stopping the trial early because an interim analysis had shown a clear benefit. Kisqali has been approved to treat hormone-driven breast cancer that has spread to other body parts, where it has taken market share from Pfizer's (PFE.N) Ibrance. Rival drug Verzenio by Eli Lilly (LLY.N) has approval in the early setting for women at high risk of recurrence after surgery. Kisqali, which saw sales gain 31% to $1.2 billion last year, is one of two new drugs with a particularly important role for the group's future sales growth. Detailed trial results will be presented at a medical conference, Novartis said, without identifying the meeting or its timing.

☆ European stocks rebound as banking jitters ease
▼ + stars: | 2023-03-27 | by ( Sruthi Shankar | ) www.reuters.com time to read: +3 min

European banks (.SX7P) rose 0.9% after shedding 3.8% on Friday, when Deutsche Bank (DBKGn.DE) sparked a rout in the sector. "Many investors still don't want to touch the banking sector for fears there is more distress to come," said Russ Mould, investment director at AJ Bell. "Yet for every bleak situation, there is always someone who sees an opportunity to make money, hence why we're seeing a rise in the share price of many European banks today." European stocks are looking to end the first quarter of the year with gains, buoyed by signs of economic resilience and hopes that central banks are near the end of their tightening cycles. However, European banks are set to end the quarter nearly flat amid the banking sector turmoil.

☆ Novartis says operating profit to grow again ahead of Sandoz spin-off
▼ + stars: | 2023-02-01 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Novartis shares were down 1.3% in early trade on Wednesday and have fallen about 11% since January 2020, underperforming most rivals. They were also disappointed by guidance for Sandoz's core operating income to decline by a "low double digit" percentage in 2023 due to cost inflation and investments to make it a stand-alone entity. MS drug Kesimpta, which requires fewer injections than standard therapies, is expected to become Novartis' second largest growth driver in 2023, after Entresto. Novartis shares lagReporting by Ludwig Burger; editing by Josephine Mason and Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

☆ Novartis says operating profit to grow again ahead of Sandoz spin off
▼ + stars: | 2023-02-01 | by ( ) www.cnbc.com time to read: +3 min

Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. We're seeing health care systems stabilize a bit more, we're seeing China start to stabilize, and we see a second-half rebound in China. All of those are important tailwinds for a business like ours," he said during an interview in Basel, Switzerland. MS drug Kesimpta, requiring fewer injections than standard therapies, is expected to become Novartis' second largest growth driver in 2023, after Entresto.

Register now for FREE unlimited access to Reuters.com RegisterSwiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. Register now for FREE unlimited access to Reuters.com RegisterIt ranked 10th in the U.S. market last year, the company added. Novartis also said it would focus in future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors and hematology medicine. The company last month said it planned to spin off Sandoz to sharpen its focus on its patented prescription medicines. Register now for FREE unlimited access to Reuters.com RegisterEditing by Mark Potter and Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Kisqali"

12 mentions found